AC Immune SA
PSE Building B - EPFL
Lausanne
CH-1015
Tel: 41-21-693-9121
Fax: 41-21-693-9120
Website: http://www.acimmune.com/
Email: info@acimmune.com
76 articles about AC Immune SA
-
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
9/5/2023
AC Immune SA (NASDAQ: ACIU) today announced that the Company will present a corporate overview and participate in one-on-one investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference, taking place virtually and in-person at the Lotte New York Palace Hotel in New York City on September 11-13, 2023.
-
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
7/28/2023
AC Immune SA today announced that Company Management will participate in a Fireside chat and one-on-one investor meetings during the BTIG Virtual Biotechnology Conference 2023, taking place on August 7-8, 2023.
-
AC Immune SA Appoints New Chief Medical Officer
7/26/2023
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced the appointment of Nuno Mendonça, MD.
-
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
6/27/2023
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its wholly-owned anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer’s disease.
-
AC Immune Holds Annual General Meeting of Shareholders
6/23/2023
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced that the Company held its Annual General Meeting per Swiss law.
-
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
4/28/2023
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the first quarter ended March 31, 2023, and provided a corporate update.
-
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
4/5/2023
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, will host a key opinion leader (KOL) webinar on early diagnosis and prevention of Alzheimer’s disease on Tuesday, April 18, 2023 at 10:30 AM EDT / 4:30 PM CEST.
-
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
3/20/2023
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that ten presentations will be delivered at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM 2023), taking place in Gothenburg, Sweden, and virtually, on March 28 – April 1, 2023.
-
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
3/16/2023
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update.
-
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
3/8/2023
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will issue a press release to report its full year 2022 financial results and provide a corporate update on March 16, 2023 at 7:00am ET.
-
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
2/7/2023
AC Immune SA (NASDAQ: ACIU) today announced prestigious new grants from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Target ALS Foundation (Target ALS) supporting research programs to enable diagnosis of TDP-43 (TAR DNA-binding protein 43).
-
AC Immune to Present at the SVB Securities Global Biopharma Conference
2/2/2023
AC Immune to Present at the SVB Securities Global Biopharma Conference Lausanne, Switzerland, February 2, 2023.
-
Phase I/II data showed AC Immune’s anti-amyloid-beta vaccine candidate could safely elicit an antibody response in patients with Alzheimer’s disease. Now, it will expand to Down Syndrome patients.
-
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
1/26/2023
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the first interim safety, tolerability and immunogenicity findings from the Phase 1b/2 ABATE trial of its anti-amyloid-beta (Abeta) vaccine ACI-24.060 in patients with prodromal Alzheimer’s disease (AD).
-
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
1/18/2023
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its collaboration partner, Life Molecular Imaging (LMI), has imaged the first patient in ADvance, the pivotal Phase 3 trial of PI-2620, a Tau PET (positron emission tomography) imaging agent for AD (Alzheimer’s disease).
-
BioSpace sat down with Roche Global Head of Neurodegeneration Rachelle Doody, Ph.D. and Alzheimer’s Drug Discovery Foundation Co-founder Howard Fillit, M.D. to discuss the highlights.
-
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
11/30/2022
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that based on the Phase 1b/2a interim data, ACI-35.030, a potential first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate, has been selected for further development.
-
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
11/23/2022
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the upcoming presentations of its vaccine technology SupraAntigen®, and of its anti-Tau and anti-Abeta investigational candidates, at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco, California (United States) and online, on November 29 – December 2, 2022.
-
Zealand Pharma and Novo Nordisk linked resources to commercialize Zegalogue for severe hypoglycemia. For that and more from a busy week across the globe, see inside.
-
Researchers have found that two common viruses—the varicella zoster and herpes simplex viruses—likely constitute a pathway that leads to Alzheimer's disease.